News

Two-thirds of patients with renal comorbidities achieved “clinical success” with the new fecal microbiota treatment for C. difficile.

At this year’s ID Week conference in Boston, Igho Ofotokun, MD, MSc, FIDSA, Grady Distinguished Professor of Medicine at the Emory University School of Medicine, shared the latest data that COVID-19 research team, RECOVER, has gathered on Long COVID and its symptoms.

Laws since 1996 have sought to assure that coverage of behavioral health treatments does not take a back seat to physical medicine. Amid a national crisis in mental illness and addiction, that new world of equality has not arrived. But is it on the way?

The chair of Harvard Medical School’s bioinformatics department says the deterministic, discrete data of billing and reimbursement means that artificial intelligence’s first big impact in healthcare is likely to be in “the business of healthcare.”

The new chief scientific officer of the Crohn’s and Colitis Foundation talked about what motivated him to pursue a career researching and taking care of Crohn’s and colitis patients.

Two drugs that target the c-MET protein are in phase 3 trials.

Payers and hospitals are at odds over proposals that would level out payments to hospital outpatient departments and physician offices.

Patterns in COVID-19 vaccinations remain largely divided along political party lines, according to one report.

Last week, a judge struck down a 2021 federal rule that allowed insurance companies to exclude pharmaceutical company copay assistance from annual deductibles.

Children with atopic dermatitis (AD) are more likely than children without AD to react to a patch test and should be referred to a specialist for evaluation.

Here’s what you need to know and do considering the DOJ’s and HHS’s drastically expanded use of digital tools to investigate and prosecute those who work in the field of healthcare, including innocent practices and providers.

The FDA approved the first biosimilar of the arthritis medication Actemra, as well as plaque psoriasis drug Zoryve for children. The agency issued a complete response letter for lebrikizumab in atopic dermatitis and for liquid formulation of botulinum toxin for frown lines, and assigned a review date for a gene therapy for a rare immune disorder. Additionally, Takeda plans to withdraw the oncology drug Exkivity from the market while Coherus resubmits BLA for Udenyca OnBody.

Authors of a recent review express that ferroptosis inhibition may be a promising pathway for treating and preventing male reproductive disorders.

A hemophilia expert makes some comparisons between the two approved gene therapies for hemophilia.

A new review and analysis suggests a combination treatment regimen for children in acute liver failure due to autoimmune hepatitis may help them maintain native liver survival.

Researchers of a phase 3 trial aimed to determine whether statins, specifically pitavastatin, could reduce the incidence of major adverse cardiovascular events among HIV patients, as the risk of cardiovascular disease is increased in those with HIV infection.

To maintain patient satisfaction and regulatory compliance and reduce potential clerical errors while maintaining high productivity, you can ease your staff’s burdens by automating your practice’s workflows and empower your staff to do more in less time.

It differs from the Pfizer and Moderna vaccine. Instead of using mRNA, the Novavax vaccines consists of proteins found in the spikes of the COVID-19 vaccine combined with an adjuvant made from the bark of a tree that grows in Chile.

ICER has weighed in on two of the 10 drugs selected for negotiations: Eliquis and Xarelto, which are among Medicare Part D’s highest spending drugs.

In a confirmatory trial, Exkivity did not meet the primary endpoint in treating patients with non-small cell lung cancer with EGFR exon 20 mutations. It will remain available while Takeda works with the FDA on withdrawal timing.

Patient organizations should focus on how they can be the most effective by leveraging their strengths to uncover new research opportunities.

The FDA has approved several new therapies this week, including a new two-component Pompe therapy, an extended-release drug for major depression without sexual side effects, and an eye drop for drug-induced dilation. Additionally, the agency has set review dates for several products, including odronextamab for blood cancers, sotatercept for pulmonary arterial hypertension, and Dupixent in young children with eosinophilic esophagitis.

Jeremy Berk, senior vice president of Risk Adjustment Solutions for PopHealthCare and Emcara Health, shares how plans must conduct a detailed analysis of how changes to risk adjustment models impact your plan in order to set an effective go-forward strategy.

Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.

Two posters presented at the European Respiratory Society International Congress found use of Dupixent improved lung function by 12 weeks with sustained responses.